What was the total decrease in fair value for Diamond Biofund Inc. in March and what caused it?

The total fair value decreased by NT$84,898 thousand in March due to stock price fluctuations in its biotech holdings.

Which two companies held by Diamond Biofund Inc. experienced the largest drops in value during March?

StemCyte and Sinphar experienced the most significant drops in value among Diamond Biofund's holdings in March.

What was the net asset value per share for Diamond Biofund Inc. at the end of March?

The net asset value per share for Diamond Biofund Inc. was NT$10.40 at the end of March.

What was the cash and cash equivalents balance for Diamond Biofund Inc. as of the end of March?

The cash and cash equivalents balance for Diamond Biofund Inc. was NT$2,733,439 thousand as of the end of March.

Why does Diamond Biofund Inc. consider its biotech investments highly volatile according to the March report?

Diamond Biofund Inc. considers its biotech investments highly volatile due to R&D outcomes that may lead to negative operating revenue when fair value declines.

AI News NQ Analysis

Diamond Biofund Announces Changes in Investment Holdings, Fair Value, Net Asset Value Per Share, and Cash Balance

NQ Score 65/100

AI Summary (NQ-processed)

鑽石生技投資公告115年3月份投資標的股數與公允價值變動，以及每股淨值與現金餘額。

AI analysis data is not yet available.

Frequently Asked Questions

Q: What was the total decrease in fair value for Diamond Biofund Inc. in March and what caused it?: A: The total fair value decreased by NT$84,898 thousand in March due to stock price fluctuations in its biotech holdings.
Q: Which two companies held by Diamond Biofund Inc. experienced the largest drops in value during March?: A: StemCyte and Sinphar experienced the most significant drops in value among Diamond Biofund's holdings in March.
Q: What was the net asset value per share for Diamond Biofund Inc. at the end of March?: A: The net asset value per share for Diamond Biofund Inc. was NT$10.40 at the end of March.
Q: What was the cash and cash equivalents balance for Diamond Biofund Inc. as of the end of March?: A: The cash and cash equivalents balance for Diamond Biofund Inc. was NT$2,733,439 thousand as of the end of March.
Q: Why does Diamond Biofund Inc. consider its biotech investments highly volatile according to the March report?: A: Diamond Biofund Inc. considers its biotech investments highly volatile due to R&D outcomes that may lead to negative operating revenue when fair value declines.